CK Life Sciences subsidiary Sequencio Therapeutics will present new research data from its primary cancer vaccine programmes at the Society for Immunotherapy of Cancer 2026 meeting. Sequencio Therapeutics to Present Cancer Vaccine Data at SITC 2026 The issuer is solely responsible for…
A new commentary published October 30, 2026, in the Journal of Clinical Oncology by Yara Abdou, MD, MSCR, and Lisa A. Carey, MD, ScM, from the University of North Carolina Lineberger Comprehensive Cancer Center, examines the evolution of genomically guided chemotherapy from MINDACT…
Bioengineer.org Subject of Research: Multicenter validation and randomized implementation of a CT-based AI risk-support system for cystic renal masses Article Title: CT-based AI risk support for cystic renal masses: multicenter validation, reader study, and a randomized implementation study News…
Nov 03, 2026, 19:00 ET SynKIR™-110 demonstrated faster tumor control with approximately 10-fold lower IFNγ and 30-fold lower TNFα and IL-2 production compared to CD28-based single-chain CAR T in preclinical models Preclinical in vivo data showed reduced exhaustion of tumor-infiltrating SynKIR™-110 T cells…
Nov 04, 2026, 19:00 ET Interim clinical data of SynKIR™-310, a CD19-targeted KIR-CAR T therapy, showed no CRS, ICANS, or DLT in the first two dose levels, coupled with robust antitumor activity in patients with relapsed or refractory B-cell non-Hodgkin Lymphoma (B-NHL) Verismo…
AllSci AstraZeneca has withdrawn its application with the European Medicines Agency (EMA) to extend capivasertib (Truqap) to newly diagnosed metastatic PTEN-deficient hormone-sensitive prostate cancer after the Committee for Medicinal Products for Human Use (CHMP) issued a provisional opinion that the…
Three peer-reviewed Signatera head and neck papers: 95.2% sensitivity, detection ~4.3 months before imaging, 100% HPV+ sensitivity. Plus members following NTRA get this by push and email at 07:00:08 ET - it reached us 8.1 seconds after publication. Written by Quantisnow AI from this release. Not…
Signatera recognized in the Medical & Healthcare category for its transformative impact on cancer care Natera also named to Fortune’s Future 120, which highlights companies poised to define the next chapter of business and innovation Natera, Inc. (NASDAQ:NTRA), a global leader…
Medicare MolDX coverage for Signatera MRD test in HCC surveillance; study showed 83% sensitivity vs 42% for AFP, 100% specificity. Plus members following NTRA get this by push and email at 07:00:11 ET - it reached us 12 seconds after publication. Written by Quantisnow AI from…
Geneva General Hospital has added a general surgeon whose specialties include surgical treatment of breast cancer, melanoma and soft tissue tumors. Dr. Nicholas Ullman, a board-certified general surgeon with fellowship training in surgical oncology, has joined the hospital’s medical staff,…
From acute infections to chronic and rare diseases—risk factors, management, and breakthroughs.
An article joins this feed when it matches these terms. Each one is also a search of its own.